A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
2상
조기 종료
NCT04916002
| 대상 질환 | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | Regeneron Pharmaceuticals |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 77 명 |
|---|
| 중재(약물) | vidutolimod, cemiplimab |
|---|
| 시작일 | 2021년 11월 30일 |
|---|
| 완료일 | 2024년 10월 31일 |
|---|
| 결과 공개일 | 2025년 12월 5일 |
|---|
요약
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: * How many participants' cancers respond to vidutolimod together with cemiplimab? * Is vidutolimod together with cemiplimab safe and well-tolerated? * How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
Objective Response Rate (ORR)
Up to 31.5 Months · Percentage of participants
| Cohort A1: CMP-001+Cemiplimab for CSCC | 44.0 Percentage of participants |
|---|
| Cohort A2: CMP-001+Cemiplimab for CSCC | 5.3 Percentage of participants |
|---|
| Cohort B1: CMP-001+Cemiplimab for MCC | 46.2 Percentage of participants |
|---|
| Cohort B2: CMP-001+Cemiplimab for MCC | 6.3 Percentage of participants |
|---|
| Cohort D: CMP-001+Cemiplimab for BCC | 25.0 Percentage of participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.